tiprankstipranks
Advertisement
Advertisement

ANAB Stock Latest News

AnaptysBio price target raised to $95 from $67 at Piper Sandler
The FlyAnaptysBio price target raised to $95 from $67 at Piper Sandler
4d ago
ANAB
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
PremiumRatings
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
5d ago
ANAB
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
PremiumCompany Announcements
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
8d ago
8K
ANAB
AnaptysBio announces $100M share repurchase program
PremiumThe Fly
AnaptysBio announces $100M share repurchase program
8d ago
ANAB
AnaptysBio board approves spin-off of First Tracks Biotherapeutics
PremiumThe Fly
AnaptysBio board approves spin-off of First Tracks Biotherapeutics
8d ago
ANAB
AnaptysBio price target raised to $90 from $70 at UBS
PremiumThe FlyAnaptysBio price target raised to $90 from $70 at UBS
18d ago
ANAB
AnaptysBio: Buy Rating on Durable Jemperli Royalties and High-Impact TRAX Pipeline Upside
Premium
Ratings
AnaptysBio: Buy Rating on Durable Jemperli Royalties and High-Impact TRAX Pipeline Upside
18d ago
ANAB
AnaptysBio price target raised to $50 from $36 at Truist
Premium
The Fly
AnaptysBio price target raised to $50 from $36 at Truist
26d ago
GSK
ANAB
AnaptysBio price target raised to $85 from $56 at Stifel
PremiumThe Fly
AnaptysBio price target raised to $85 from $56 at Stifel
1M ago
ANAB
Risks Loom for AnaptysBio’s Proposed Breakup: Market Value, Volatility and Execution Challenges Highlighted
PremiumCompany Announcements
Risks Loom for AnaptysBio’s Proposed Breakup: Market Value, Volatility and Execution Challenges Highlighted
1M ago
ANAB
AnaptysBio: Structural Separation and Advancing Autoimmune Pipeline Support Overweight Rating and Value Upside
PremiumRatings
AnaptysBio: Structural Separation and Advancing Autoimmune Pipeline Support Overweight Rating and Value Upside
1M ago
ANAB
AnaptysBio price target raised to $66 from $51 at H.C. Wainwright
PremiumThe Fly
AnaptysBio price target raised to $66 from $51 at H.C. Wainwright
1M ago
ANAB
AnaptysBio price target raised to $79 from $78 at Barclays
PremiumThe FlyAnaptysBio price target raised to $79 from $78 at Barclays
1M ago
ANAB
AnaptysBio provides update on potential spin-off of biopharma operations
Premium
The Fly
AnaptysBio provides update on potential spin-off of biopharma operations
1M ago
GSK
ANAB
AnaptysBio reports Q4 EPS $1.58, consensus 93c
Premium
The Fly
AnaptysBio reports Q4 EPS $1.58, consensus 93c
1M ago
ANAB
AnaptysBio price target raised to $78 from $55 at Barclays
PremiumThe Fly
AnaptysBio price target raised to $78 from $55 at Barclays
2M ago
ANAB
AnaptysBio assumed at Buy from Neutral at UBS
PremiumThe Fly
AnaptysBio assumed at Buy from Neutral at UBS
3M ago
ANAB
These 3 Biotech Stocks Can Triple from Current Levels, Say Five-Star Analysts – 12/19/2025
PremiumMarket News
These 3 Biotech Stocks Can Triple from Current Levels, Say Five-Star Analysts – 12/19/2025
4M ago
ANAB
LBRX
AnaptysBio price target raised to $140 from $100 at Guggenheim
PremiumThe Fly
AnaptysBio price target raised to $140 from $100 at Guggenheim
4M ago
ANAB
AnaptysBio price target lowered to $55 from $70 at Barclays
PremiumThe FlyAnaptysBio price target lowered to $55 from $70 at Barclays
4M ago
ANAB
AnaptysBio price target lowered to $56 from $80 at Stifel
Premium
The Fly
AnaptysBio price target lowered to $56 from $80 at Stifel
4M ago
ANAB
AnaptysBio Files Legal Complaint Against GSK and Tesaro
Premium
Company Announcements
AnaptysBio Files Legal Complaint Against GSK and Tesaro
4M ago
8K
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >